WELL Health and HEALWELL AI Launch WELLTRUST to Empower Patients and Accelerate AI Powered Ethical Patient Identification for Clinical Research

Executive Summary

• WELL Health Technologies Corp. and HEALWELL AI announced the launch of WELLTRUST™, a consent‑driven patient‑identification platform that integrates WELL’s clinic network with HEALWELL’s DARWEN™ AI to accelerate clinical‑trial recruitment while preserving privacy.
• The platform provides patients with revocable consent controls and creates a scalable, compliant data infrastructure for pharmaceutical sponsors and research organizations.
• Executives highlighted the strategic importance of the launch for expanding real‑world evidence generation, future research use cases, and strengthening WELL’s position in the health‑tech ecosystem.

Key Details

• Platform Name: WELLTRUST™ – consent‑first data governance and patient‑identification solution.
• Scope: First phase deployed across WELL‑operated clinics in Canada; designed for expansion to additional use cases (real‑world evidence, clinical decision support).
• Core Capabilities:
• Secure, patient‑centric consent framework allowing patients to opt‑in or decline participation in research.
• AI‑enabled identification of “high‑fit” patients with chronic, rare, and complex conditions using HEALWELL’s DARWEN™ platform.
• Unified privacy, consent, and data‑governance layer meeting Canadian regulatory standards.
• Strategic Benefits:
• Accelerates clinical‑trial recruitment by building a database of consented participants.
• Enhances partnership opportunities with pharmaceutical sponsors, research organizations, and trial networks.
• Positions WELL as a provider of scalable, privacy‑preserving data infrastructure for the life‑sciences ecosystem.
• Executive Comments:
• Dr. Alexander Dobranowski (President, HEALWELL AI) emphasized responsible AI and patient autonomy.
• Dr. Michael Frankel (Chief Medical Officer, WELL Health) called the launch a “major step forward” in empowering patients and supporting next‑generation therapeutics.
• Future Outlook: Platform designed to support additional applications such as real‑world evidence generation and enhanced clinical decision‑support tools.

Notable Quotes

“WELLTRUST embodies our commitment to responsible and impactful AI in healthcare… This will accelerate research and patient access to potentially life‑saving innovations while respecting high standards of privacy and patient autonomy.” – Dr. Alexander Dobranowski, President, HEALWELL AI

“This launch marks a major step forward in our mission to empower patients and improve healthcare outcomes through the use of technology… We are proud to formalize this next phase of innovation through our collaboration with HEALWELL.” – Dr. Michael Frankel, Chief Medical Officer, WELL Health

Materiality Assessment: Material – Positive (the launch introduces a new, revenue‑generating service that could materially impact future growth and partnership opportunities).